- Over 25 years of legal experience with leading healthcare
organizations, including GW Pharmaceuticals, Actelion
Pharmaceuticals, Eisai, GSK, and the U.S. FDA
SOUTH
SAN FRANCISCO, Calif., Sept. 18,
2024 /PRNewswire/ -- IDEAYA Biosciences, Inc.
(NASDAQ: IDYA), a precision medicine oncology company committed to
the discovery and development of targeted therapeutics, today
announced that Douglas B. Snyder,
joined the company as its Senior Vice President, General Counsel on
September 18, 2024.
"Doug brings a broad legal background in the healthcare field
spanning biotechnology, pharmaceuticals and the FDA. He has
developed extensive commercial and international experience across
multiple organizations that makes him well-equipped to lead
IDEAYA's legal functions as we continue to build a leading global
precision medicine oncology company," said Yujiro S. Hata, President and Chief Executive
Officer of IDEAYA Biosciences.
"I am excited to join IDEAYA during this exciting growth phase
as the company prepares for potential commercialization of
Darovasertib and broadens its clinical pipeline efforts, including
in MTAP-deletion. I look forward to partnering with the management
team and the broader organization to advance our collective mission
to deliver transformative precision medicines to cancer patients,"
said Douglas B. Snyder.
Mr. Snyder most recently served as Executive Vice President,
Chief Legal Officer and Secretary at GW Pharmaceuticals (NASDAQ:
GWPH) from 2017 to 2022 through the $7.2
billion acquisition by Jazz Pharmaceuticals. From 2012 to
2017, Mr. Snyder led the legal and compliance teams as Senior Vice
President, General Counsel, and Secretary for Actelion
Pharmaceuticals (NASDAQ: ATLN) through the $30 billion acquisition by Johnson and Johnson.
Prior to that, Mr. Snyder held the position of Senior Vice
President, General Counsel, Secretary at Eisai Inc., from 2005 to
2011. From 1999 to 2005, Mr. Snyder was Vice President, Associate
General Counsel for GSK. From 1994 to 1999, Mr. Snyder was
Associate General Counsel at the U.S. Food & Drug
Administration (FDA). Mr. Snyder holds a J.D. from the Catholic University of America, Columbus School of Law and a B.A. from
Dickinson College.
About IDEAYA Biosciences
IDEAYA is a synthetic
lethality-focused precision medicine oncology company committed to
the discovery and development of targeted therapeutics for patient
populations selected using molecular diagnostics. IDEAYA's approach
integrates capabilities in identifying and validating translational
biomarkers with drug discovery to select patient populations most
likely to benefit from its targeted therapies. IDEAYA is applying
its early research and drug discovery capabilities to synthetic
lethality – which represents an emerging class of precision
medicine targets.
Forward-Looking Statements
This press release contains
forward-looking statements, including, but not limited to,
statements related to the Company's potential commercialization of
Darovasertib and efforts to broaden its clinical pipeline. IDEAYA
undertakes no obligation to update or revise any forward-looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of IDEAYA in general, see IDEAYA's Annual
Report on Form 10-K dated February 20,
2024 and any current and periodic reports filed with the
U.S. Securities and Exchange Commission.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
SVP, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-appoints-douglas-b-snyder-as-senior-vice-president-general-counsel-302250621.html
SOURCE IDEAYA Biosciences, Inc.